Generative AI In Life Sciences: Unlocking Operational Value Across the Product Lifecycle

Аннотация

The development and commercialization of PUBLISHED 26 July 2025 VOLUME Vol.07 Issue 07 2025 pharmaceutical and MedTech products represent one of the most complex and resource-intensive endeavors in CITATION the modern economy. The process involves long timelines, high attrition rates, and the integration of vast COPYRIGHT volumes of structured and unstructured data. © 2025 Original content from this work may be used under the terms of the creative commons attributes 4.0 License. Generative artificial intelligence (GenAI) has emerged as a transformative tool capable of enhancing efficiency, accelerating scientific discovery, and streamlining operations across the life sciences value chain - from early research to clinical development, manufacturing, medical affairs, and commercialization. A synthesis of current literature, real-world implementations, and industry benchmarks was conducted to evaluate high-impact application areas of GenAI in life sciences. Documented use cases from biopharmaceutical and MedTech organizations illustrate the deployment of GenAI in target identification, de novo molecule generation, trial protocol design, medical writing automation, manufacturing deviation analysis, medical engagement support, and omnichannel content generation. Estimates indicate that GenAI could unlock between $60 billion and $110 billion in annual value across the pharmaceutical industry. The greatest economic potential lies in commercial functions, followed by research and clinical development. Early adopters - including Pfizer, Novartis, AstraZeneca, and Novo Nordisk - have reported productivity improvements ranging from 20% to 60% in pilot programs focused on regulatory documentation, manufacturing quality, and HCP engagement. The American Journal of Medical Sciences and Pharmaceutical Research 15 https://www.theamericanjournals.com/index.php/tajmspr The American Journal of Medical Sciences and Pharmaceutical Research Despite these benefits, large-scale adoption remains personalization at scale [1][2]. constrained by several challenges. Key barriers include However, capturing this value is far from plug-and-play. hallucination risks in language models, regulatory The successful application of GenAI depends not only on ambiguity, limitations in technical infrastructure and the quality of foundation models, but also on the data quality, and resistance to organizational change. readiness of underlying data architectures, the ability to Addressing these constraints will be critical to ensuring embed new workflows into operating models, and the the safe, compliant, and impactful integration of GenAI strength of governance frameworks addressing technologies into life sciences workflows. regulatory, ethical, and security risks [9]. Keywords: Generative AI; Life sciences; Pharmaceutical This article explores the most promising applications of operations; Pharma digital transformation GenAI across the life sciences value chain. Drawing on proprietary insights, industry case examples, and 1. Introduction emerging benchmarks, we provide a high-level The development and commercialization of framework to assess where GenAI can unlock pharmaceutical and MedTech products is among the meaningful value - from R&D to market - and how most complex and data-intensive undertakings in the companies can approach adoption responsibly and modern economy. Spanning over a decade, involving effectively [2][3]. billions of dollars in investment, and requiring 2. Materials and Methods navigation through rigorous scientific, regulatory, operational, and commercial hurdles, the process is This article synthesizes insights from recent external inherently high-risk and high-cost. Companies must publications, scientific literature, and publicly disclosed synthesize vast volumes of structured and unstructured examples of Generative AI (GenAI) adoption across the data - from genomic sequences and digital pathology life sciences industry. The analysis is structured around slides to clinical trial reports, supply chain metrics, and five stages of the pharmaceutical and MedTech value real-world patient data - across siloed systems and chain: research and early discovery, clinical globally distributed teams. development, manufacturing and supply chain, medical affairs, and commercialization. In this environment, Generative AI (GenAI) has emerged as a transformative technology with the potential to Use cases were selected based on clear evidence of real- fundamentally reshape how organizations discover, world implementation, business relevance, and develop, and deliver therapies. Unlike traditional availability of verifiable impact metrics. Preference was analytical AI, which has already shown impact through given to examples disclosed by leading organizations in classification and prediction tasks, GenAI introduces the industry, including pharmaceutical, biotechnology, novel capabilities such as large-scale content and medical device companies, t